The FDA has approved telotristat ethyl (Xermelo) tablets for the treatment of patients with carcinoid syndrome diarrhea that has not responded to somatostatin analogs alone.
The FDA has expanded the approval of lenalidomide to include its use as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant.
Long-term data from the phase III BC2001 trial confirmed that adding chemotherapy to radiation therapy improves locoregional control and reduces the rate of salvage cystectomy in patients with muscle-invasive bladder cancer.
Results from a phase I/II study suggest that the immunotherapy nivolumab is safe and effective in advanced hepatocellular carcinoma (HCC).
A Swedish study found that 3D tomosynthesis screening detected 40% more cases of breast cancer compared with traditional digital mammography.
The appearance of bone metastases on FDG PET/CT was influenced by breast cancer histology, with non-FDG-avid lesions more common in invasive lobular carcinoma patients.
In a mouse model, researchers found that TRAIL-R2 inhibition prevented bone metastases, suggesting a possible therapeutic strategy for breast cancer patients.
A small retrospective study of heavily pretreated patients with chronic myeloid leukemia found bosutinib to be a good option in the fourth-line setting.
The risk of bone metastases from GISTs, though rare, should be considered during long-term follow-up of patients, especially in those with liver metastases.
The US Food and Drug Administration has approved dinutuximab (Unituxin) for the treatment of high-risk neuroblastoma in pediatric patients.